E7 TCR T Cell Immunotherapy for High-Grade Cervical Intraepithelial Neoplasia

Background: * Cervical Intraepithelial Neoplasia (CIN) is caused by persistent infection with the Human Papillomavirus (HPV). * High-grade lesions are common, affecting 5% of the female population in the United States, and are more likely to progress to cervical cancer. * Surgical and ablative therapies are effective but can lead to long-term morbidity. New treatment modalities are needed. * E7 TCR T cells have demonstrated safety and clinical activity in treatment-refractory metastatic HPV+ cancers. Objectives: \- To determine the safety of intralesional injection of E7 TCR T cells as therapy for high- grade CIN. Eligibility: \- Patients greater than or equal to 21 years of age with HPV16-associated, high-grade CIN. Design: * This is a phase I clinical trial with a 3+3 dose escalation design. * Patients will receive intralesional injections of E7 TCR T cells. * Patients will not receive a conditioning chemotherapy regimen or systemic aldesleukin.